IPSEF

Ipsen S.A

IPSEF, USA

Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injection for the treatment of pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer; Tazverik, a chemotherapy-free EZH2a inhibitor that is in phase III clinical trial for the treatment of second line follicular lymphoma; Tovorafenib that is in phase III clinical trial to treat first line pediatric Low-Grade Gliomas and is In phase II clinical trial for the treatment of relapsed/refractory pediatric Low-Grade Gliomas; and IPN01194 and IPN01195 that is in phase I to treat solid tumors. The company is also developing products for rare disease comprising Bylvay for the treatment of progressive familial intrahepatic cholestasis; Iqirvo, a peroxisome proliferator-activated receptor agonist to treat primary biliary cholangitis; NutropinAq, a liquid formulation of recombinant human growth hormone; Increlex, a recombinant human insulin-like growth factor; Fidrisertib that is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressive; Ritivixibat that is in phase II clinical trial to treat primary sclerosing cholangitis. In addition, it develops neuroscience products, such as Dysport that is in phase III clinical trial for the treatment of chronic and episodic migraine; and IPN10200 that is in phase II to treat aesthetic and therapeutic indications. The company has a partnership with Simcere Zaiming Pharmaceutical Co., Ltd. for the development of SIM0613, a protein expressed on varies tumor types and cancer-associated fibroblasts. The company was founded in 1929 and is headquartered in Paris, France.

https://www.ipsen.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
IPSEF
stock
IPSEF

IPSEF Global 2026 Relocate magazine

Read more →
IPSEF
stock
IPSEF

Ipsen rises on FDA breakthrough therapy status for blood cancer therapy Seeking Alpha

Read more →

Showing 2 of 9

Finn Analysis

(Last Updated 2025-06-30)

Health Score

Price to Earnings Ratio (P/E)

-

High

18.07

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

High

2.23

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Low

9.30 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Medium

5.76 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

25.90 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Medium

0.61

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of Ipsen S.A

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

—

Latest Release

Date

2021-03-31

EPS Actual

2.1499

EPS Estimate

0

EPS Difference

2.1499

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-06-30)

Deep Value
Potential Value Candidate(5.5)
Defensive
Highly Defensive(6.5)
Dividend
Decent Dividend Payer(3.5)
Economic Moat
Wide Moat Company(7.5)
GARP
Fair GARP(6)
Growth
Moderate Growth(5)
Momentum
Moderate Momentum(3.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
High Quality(7.5)
Value
Undervalued(6.5)

Income Statement

(Last Updated 2025-06-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-06-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-06-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.